GlassScriptPhysician profile
Divijani D Puttagunta
NPI 1982815999
$2,283.17
in general payments reported to CMS, 2019-2025
31 companies · $640 in 2025
The $640 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $79.30 · 2021: $213 · 2022: $417 · 2023: $278 · 2024: $374 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,292.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $398.28 | 2022-2025 | |
| Abbvie INC. | $279.88 | 2021-2025 | |
| Novo Nordisk INC | $250.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $203.90 | 2019-2025 | Evenity, Krystexxa, Prolia |
| Glaxosmithkline, LLC. | $147.60 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.98 | 2019-2025 | Jardiance, Jascayd |
| Astrazeneca Pharmaceuticals LP | $127.26 | 2019-2023 | Farxiga |
| Astellas Pharma US INC | $106.04 | 2019-2023 | Veozah |
| Abbott Laboratories | $95.45 | 2025 | Freestyle Libre 3, Eterna, Esprit |
| Sumitomo Pharma America, INC. | $49.87 | 2024-2025 | Gemtesa |
| Madrigal Pharmaceuticals | $45.38 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $43.39 | 2019-2022 | |
| Lilly USA, LLC | $38.12 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $35.39 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.19 | 2022-2023 | Xifaxan |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $28.21 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Alnylam Pharmaceuticals INC. | $24.71 | 2023 | Oxlumo |
| Merck Sharp & Dohme LLC | $24.24 | 2020-2022 | |
| Sanofi Pasteur INC. | $22.18 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $22.00 | 2024 | |
| Amarin Pharma, INC. | $21.02 | 2022 | |
| Gilead Sciences, INC. | $19.79 | 2025 | |
| Amneal Pharmaceuticals LLC | $18.19 | 2025 | Unithroid |
| Lundbeck LLC | $17.38 | 2025 | Rexulti |
| Vbi Vaccine (Delaware) INC. | $15.72 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.24 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.88 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.85 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.41 | 2021 | |
| Allergan, INC. | $12.26 | 2020 | |
| Genentech USA, INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Divijani Puttagunta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.